Read Time: 2 mins

131/QRS duration after cardiac resychronisation therapy

Copy Link
Published Online: Oct 3rd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr131
Authors: C Little (Presenting Author) - The Great Western Hospital, Swindon, UK;K Lees - The Great Western Hospital, Swindon, UK; R McCrea - The GreatWestern Hospital, Swindon, UK; A Biney - The Great Western Hospital,Swindon, UK; F Shah - The Great Western Hospital, Swindon, UK
Quick Links:
Article Information

Background: CRT (cardiac resynchronisation therapy) is widely known for improving LV (left ventricular) function in patients with heart failure and dyssynchrony. However, it is unsuccessful in approximately 30–40% of all implants. There have been many studies that have looked at multiple factors to predict response. During a CRT implant – one of the main aims is to narrow the QRS, however there have been very few studies investigating an association between the QRS duration (QRSd) post implant and response to cardiac resynchronisation therapy (CRT). Takenaka et al. (2018) study showed the QRS width may be a predictor of response as it correlated with an improvement of LV end-systolic volume. The aim of this study was to determine if there is an association between the narrowing the QRS and response in patients with biventricular pacemakers by evaluating EF (ejection fraction) and LV function.

Methods: This retrospective study included 46 patients, all of whom had a CRT device implanted between the years of 2017–8. Responders to CRT were defined as those having a greater or equal to 10% increase in EF by echocardiography at the 6-month follow up or an improvement in LV function. The QRSd was analysed in precordial lead – V1, pre and post CRT implant, and compared to the non-responder group. Clinical characteristics are shown in Table 1. All patients had a 12-lead ECG before and after implant (during biventricular pacing).

Results: Based on the echocardiographic data at 6 months post CRT implant, 29 patients (63.04%) were considered responders and 17 (36.95%) were considered non responders. The QRSd post CRT was then analysed between the responder and non-responder groups.

The responder group had a mean QRS reduction of 30 ± 5ms, where-as the non-responder group had a mean QRS reduction of 8 ± 6ms. All the patients in the responder group had a QRS reduction of at least 20%, with a maximum reduction of 74 ms (60% reduction). Patients with a <20% reduction in QRS, had a worse outcome – with no improvement on their LV function or EF. Lead repositions were performed on five patients, and were associated with worse outcomes such as no improvement in LV function. This indicates patients need a reduction in QRSd during CRT implant to improve mortality and morbidity and increase their chance of responding. The limitation of this study is that this is a single lead measurement, more in-depth studies, looking at QRSd globally, across the precordial leads, could be the next step to predicting response in CRT patients.


1. Takenaka MT, Inden Y, Yanagisawa S, et al. Myocardial viability as shown
by left ventricular lead pacing threshold and improved dyssynchrony
by QRS narrowing predicts the response to cardiac resynchronisation
therapy. J Cardiovasc Electrophysiol. 2018;30(3):311–9.

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72